Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
2,098 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Fenaux P, Platzbecker U, Mufti GJ, et al. · N Engl J Med · 2020Clinical Trial, Phase III, Multicenter Study
- Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial.
Meyer EH, Salhotra A, Gandhi AP, et al. · Blood · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW, Trenschel R, Stelljes M, et al. · Lancet Haematol · 2020Clinical Trial, Phase III, Randomized Controlled Trial
- Luspatercept for patients with lower-risk myelodysplastic syndromes/neoplasms: a systematic review and meta-analysis.
Alhajahjeh A, Woite NL, Rolles B, et al. · Blood Adv · 2025Systematic Review, Meta-Analysis
- Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Platzbecker U, Santini V, Fenaux P, et al. · Lancet · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial.
Della Porta MG, Garcia-Manero G, Santini V, et al. · Lancet Haematol · 2024Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, et al. · Lancet · 2023Randomized Controlled Trial, Clinical Trial, Phase III
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. · Lancet Oncol · 2009Clinical Trial, Phase III, Comparative Study
- Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis.
Kilic B, Sacin E, Tanin MK, et al. · Ann Hematol · 2025Systematic Review, Meta-Analysis
- Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, et al. · Lancet Haematol · 2024Randomized Controlled Trial, Clinical Trial, Phase III
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, et al. · N Engl J Med · 2007Comparative Study, Multicenter Study
- Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL, Pasquini MC, Logan BR, et al. · J Clin Oncol · 2017Clinical Trial, Phase III, Comparative Study
- Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW, Stelljes M, Reményi P, et al. · Am J Hematol · 2022Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Scott BL, Pasquini MC, Fei M, et al. · Transplant Cell Ther · 2021Randomized Controlled Trial, Research Support, N.I.H., Extramural
- CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.
Shimony S, Murdock HM, Keating J, et al. · Blood Adv · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, et al. · Blood Adv · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.
Yang J, Jia Y, Hu X, et al. · Blood · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial.
Garcia-Manero G, Santini V, Zeidan AM, et al. · Adv Ther · 2025Randomized Controlled Trial, Clinical Trial, Phase III
- Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis.
Liu H, Yang N, Meng S, et al. · Clin Exp Med · 2020Meta-Analysis, Systematic Review
- Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).
Oliva EN, Riva M, Niscola P, et al. · J Clin Oncol · 2023Clinical Trial, Phase II, Multicenter Study
- Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis.
Khanam R, Shahzad M, Chaudhary SG, et al. · Leuk Lymphoma · 2022Meta-Analysis, Systematic Review
- Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
Sasaki K, Jabbour E, Montalban-Bravo G, et al. · NEJM Evid · 2022Randomized Controlled Trial
- Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.
DeZern AE, Thepot S, de Botton S, et al. · Blood Adv · 2025Clinical Trial, Phase III, Randomized Controlled Trial
- Pre-transplant therapy for patients with myelodysplastic syndromes: A systematic review and meta-analysis.
Wang H, Li Y, Zhou W, et al. · Leuk Res · 2021Meta-Analysis, Research Support, Non-U.S. Gov't
- Ocular Features of VEXAS Syndrome: A Systematic Review and Meta-analysis.
Quigley C, Pietris J, Ang T, et al. · Am J Ophthalmol · 2025Systematic Review, Meta-Analysis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.